Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Itamar Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ITMR is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ITMR's weekly volatility (6%) has been stable over the past year.
7 Day Return
IL Medical Equipment
1 Year Return
IL Medical Equipment
Return vs Industry: ITMR matched the IL Medical Equipment industry which returned 65.2% over the past year.
Return vs Market: ITMR exceeded the IL Market which returned 37.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Itamar Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StDo Insiders Own Lots Of Shares In Itamar Medical Ltd. (TLV:ITMR)?
1 month ago | Simply Wall StItamar Medical Ltd. (TLV:ITMR): Is Breakeven Near?
2 months ago | Simply Wall StAnnouncing: Itamar Medical (TLV:ITMR) Stock Increased An Energizing 146% In The Last Three Years
Is Itamar Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ITMR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ITMR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ITMR is unprofitable, so we can't compare its PE Ratio to the IL Medical Equipment industry average.
PE vs Market: ITMR is unprofitable, so we can't compare its PE Ratio to the IL market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ITMR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ITMR is overvalued based on its PB Ratio (7.7x) compared to the IL Medical Equipment industry average (3x).
How is Itamar Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITMR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ITMR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ITMR's is expected to become profitable in the next 3 years.
Revenue vs Market: ITMR's revenue (22.4% per year) is forecast to grow faster than the IL market (8.5% per year).
High Growth Revenue: ITMR's revenue (22.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ITMR's Return on Equity is forecast to be high in 3 years time
How has Itamar Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ITMR is currently unprofitable.
Growing Profit Margin: ITMR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ITMR is unprofitable, but has reduced losses over the past 5 years at a rate of 6.4% per year.
Accelerating Growth: Unable to compare ITMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITMR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (21.6%).
Return on Equity
High ROE: ITMR has a negative Return on Equity (-25.4%), as it is currently unprofitable.
How is Itamar Medical's financial position?
Financial Position Analysis
Short Term Liabilities: ITMR's short term assets ($57.4M) exceed its short term liabilities ($18.0M).
Long Term Liabilities: ITMR's short term assets ($57.4M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: ITMR's debt to equity ratio (12.3%) is considered satisfactory.
Reducing Debt: ITMR's debt to equity ratio has reduced from 88.6% to 12.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ITMR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ITMR has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 3.5% each year.
What is Itamar Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITMR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ITMR's dividend in 3 years as they are not forecast to pay a notable one for the IL market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gilad Glick (47 yo)
Mr. Gilad Glick has been the Chief Executive Officer and President of Itamar Medical Ltd., since July 1, 2013 and served as its Acting Vice President of Marketing and Sales. He served as an Acting Presiden...
CEO Compensation Analysis
Compensation vs Market: Gilad's total compensation ($USD911.00B) is above average for companies of similar size in the IL market ($USD683.50K).
Compensation vs Earnings: Gilad's compensation has increased whilst the company is unprofitable.
Experienced Management: ITMR's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: ITMR's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Itamar Medical Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Itamar Medical Ltd.
- Ticker: ITMR
- Exchange: TASE
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: ₪1.055b
- Shares outstanding: 491.61m
- Website: https://www.itamar-medical.com
Number of Employees
- Itamar Medical Ltd.
- 9 Halamish Street
- North Industrial Zone
Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical device...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 16:16|
|End of Day Share Price||2021/04/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.